Home

Stephen Kanes

CIK 1612859 · Chief Medical Officer · last filed 2026-06-24

Stephen Kanes is a Chief Medical Officer who has filed 28 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$14.4M, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

28

Lifetime Open-Market Net

-$14.44M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Centessa Pharmaceuticals plc (CNTA) Delisted Chief Medical Officer 0 $40.50 $0 $0 3 2026-06-24
Sage Therapeutics, Inc. (SAGE) Delisted Chief Medical Officer 14,591 $8.68 $126.6K -$14.44M 25 2021-10-21

Recent Filings

28 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-24 Centessa Pharmaceuticals plc (CNTA) Delisted Disp (D) −120,000 $0 EDGAR
2026-02-03 Centessa Pharmaceuticals plc (CNTA) Delisted Grant (A) +120,000 $0 EDGAR
2025-02-04 Centessa Pharmaceuticals plc (CNTA) Delisted Grant (A) — $0 EDGAR
2021-10-21 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +2,680 -$45.1K EDGAR
2021-06-17 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +2,499 -$58.9K EDGAR
2021-02-12 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2020-04-30 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2020-02-14 Sage Therapeutics, Inc. (SAGE) Delisted Grant (A) — $0 EDGAR
2019-09-05 Sage Therapeutics, Inc. (SAGE) Delisted Exer (M) +6,000 $2.7K EDGAR
2019-07-29 Sage Therapeutics, Inc. (SAGE) Delisted Mixed +1,351 -$88.6K EDGAR
Showing 1–10 of 28
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.